OROGO NEWS & INSIGHTS
Technical articles on nucleoside and oligonucleotide chemistry
Practical articles about the questions that come up before you commit to a material: which intermediate survives scale-up, what a purity number is actually measuring, which sulfurizing reagent suits your sequence. Each one ends with the public literature it draws on, so you can check the reasoning rather than take our word for it.
Latest articles
The most recently published OROGO technical and industry perspectives.
Coupling Activators in Oligonucleotide Synthesis: Reading the DCI Evidence Carefully
What the 1998 DCI experiments show—and why activator comparisons must retain substrate, loading and process conditions.
Molecular chemistry · Read article
2′-Fluoro Phosphoramidites: From Solid-Phase Synthesis to Duplex Behavior
What defined solid-phase, thermodynamic, structural and NMR studies show—and why 2′-F results remain sequence-bound.
RNA and nucleotides · Read article
RNA-Based Skincare Is Becoming a Materials Question
Why PDRN, siRNA, miRNA and tFNA need separate material definitions, evidence boundaries and formulation reviews.
Conjugation and delivery · Read articleIndustry Insights
What deals and clinical results in this field mean for the people supplying its chemistry.
INTerpath-001 Is Positive, but the Phase 3 Effect Size Is Still Missing
What the positive INTerpath-001 topline result establishes—and what remains unknown until the full Phase 3 data are released.
Industry and scale-up · Read articleAPOC3 Oligonucleotides Advance on Two Regulatory Tracks
Why the 2026 TRYNGOLZA and REDEMPLO actions must be read by exact modality, indication, and regulatory history.
Industry and scale-up · Read articleNovartis Paid $12 Billion for Avidity. The Structure Is the Interesting Part.
The carve-out splits the AOC platform by tissue, not by technology — and leaves the Bristol Myers Squibb and Lilly collaborations outside Novartis.
Industry and scale-up · Read articleTechnical Articles
Literature-linked technical content that answers practical questions before material selection or project review.
Arrowhead's P=S Detour to a 5′-Cyclopropyl Phosphonate
A stalled 1,4-addition became a workable cyclopropanation after a temporary P=O-to-P=S redesign.
Molecular chemistry · Read articleAntibody-Oligonucleotide Conjugates: Three Coupled Development Problems
Why antibody targeting, conjugation chemistry and oligonucleotide design have to be developed as one system.
Conjugation and delivery · Read articleWhat the Data Says About Stereodefined Phosphorothioate
The literature does not say stereopure is better — it says the pattern matters, and all-Rp fails in vivo.
Molecular chemistry · Read articleEnzymatic DNA Synthesis: What It Threatens, and What It Does Not
The papers name two real limits of phosphoramidite chemistry. Then look at what the enzymes actually made.
RNA and nucleotides · Read articleEstablished Chemistry Buys You a Smaller Regulatory Package
An industry consortium white paper says the quiet part: novel chemistry costs more than synthesis time.
Industry and scale-up · Read articleOligonucleotide Capacity Is Measured in Moles, and the Numbers Are Small
What a $126 million plant expansion buys, and why published capacity figures should not be trusted.
Industry and scale-up · Read articleCyclic Dinucleotides: Why the Backbone Is Sulfurized
What the phosphorothioate does for a STING agonist, and what the first-in-class phase I actually reported.
Molecular chemistry · Read articleHow to Choose Nucleoside Intermediates for Scale-Up
Review route robustness, impurity profile, purification strategy, raw-material supply and batch documentation.
Molecular chemistry · Read articleKey Quality Attributes for Modified Nucleotides
Review salt form, water content, storage, enzymatic compatibility, purity basis and analytical method selection.
RNA and nucleotides · Read articleSulfurizing Reagents for Oligonucleotide Synthesis
Compare solubility, reaction rate, byproducts, stability and process compatibility.
Molecular chemistry · Read articleProcess Development Challenges in Nucleoside Manufacturing
Review protecting-group strategy, crystallization, residual impurities and reproducibility.
Industry and scale-up · Read articleWhat to Consider When Sourcing Cap Analogs
Align cap architecture, purity basis, counterion, storage and IVT workflow requirements.
RNA and nucleotides · Read articleGalNAc Linker Chemistry for Oligonucleotide Research
Compare ligand valency, linker architecture, attachmentchemistry and analytical strategy.
Conjugation and delivery · Read articleUse these resources in project planning
Start with a technical article when comparing a chemistry family or quality attribute. Use the product catalog for a named material, or send a structure and specification when the target requires custom review.